Please ensure Javascript is enabled for purposes of website accessibility

This Potentially Game-Changing News Sent AmerisourceBergen Corp. as Much as 14% Higher

By Sean Williams - Updated Feb 13, 2018 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the drug-distribution industry, deal-making may still be in the air.

What happened

Shares of AmeisourceBergen (ABC -0.21%), a distributor of brand-name and generic drugs and a pharmacy supply chain management company, soared by as much as 14% Tuesday after The Wall Street Journal reported before the opening bell that Walgreens Boots Alliance (WBA 0.04%) is considering a buyout bid for the company.

The stock is up about 9% as of 3:30 p.m. EST. 

So what

According to reports, Walgreens CEO Stefano Pessina spoke with representatives of AmerisourceBergen CEO Steven Collis about the possibility of a buyout a few weeks ago. Walgreens already owns 26% of AmerisourceBergen. Though no official offer has been made by Walgreens Boots Alliance, the recent developments in a rapidly consolidating drug-distribution industry are certainly causing a stir. 

Prescription capsules lying atop hundred-dollar bills.

Image source: Getty Images.

These rumors follow last month's announcement that JPMorgan Chase,, and Berkshire Hathaway were joining forces to create a nonprofit healthcare venture to lower costs and improve healthcare services for their employees. They also come just a little over two months after rival CVS Health announced that it would be purchasing Aetna for $69 billion. This fight for market share and lower costs could take a further toll on already-tightening margins, which could be the impetus behind Walgreens' attempt to feel out AmerisourceBergen.

Now what

Does a tie-up between these companies make sense? The answer is murky at best.

Clearly, purchasing AmerisourceBergen would give Walgreens a greater reliance on the U.S. market for profits and sales. Since the U.S. lacks a lot of the drug-pricing controls found in Europe, this would likely mean stronger profitability. But it's not clear what additional value adding AmerisourceBergen would have, considering that AmerisourceBergen is currently focusing on its own business-expansion opportunities. Not to mention that Walgreens' integration of Rite Aid and subsequent closure of around 600 stores could create combination hiccups if Walgreens pursues AmerisourceBergen. 

For the time being, I wouldn't read too much into this chatter. Whatever your investment thesis was on AmerisourceBergen yesterday should still stand today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$41.66 (0.04%) $0.01
AmerisourceBergen Corporation Stock Quote
AmerisourceBergen Corporation
$148.15 (-0.21%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.